艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABBV 艾伯维公司

盘后交易 05-11 18:29:57 EDT

202.78

+1.23

+0.61%

盘后202.99

+0.21+0.10%

18:24 EDT

最高205.38	最低202.01	成交量463.74万
今开202.01	昨收201.55	日振幅1.67%
总市值3,584亿	流通市值3,575亿	总股本17.67亿
成交额9.42亿	换手率0.26%	流通股本17.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":202.78,"timestamp":1778529600000,"preClose":201.55,"halted":0,"volume":4637379,"hourTrading":{"tag":"盘后","latestPrice":202.99,"preClose":202.78,"latestTime":"18:24 EDT","volume":688608,"amount":139635854.49311998,"timestamp":1778538268858,"change":0.21,"changeRate":0.001036,"amplitude":0.006953},"delay":0,"changeRate":0.006102704043661571,"floatShares":1762950764,"shares":1767384632,"eps":2.030053,"marketStatus":"盘后交易","change":1.23,"latestTime":"05-11 18:29:57 EDT","open":202.01,"high":205.375,"low":202.01,"amount":941826818.54856,"amplitude":0.016696,"askPrice":204.95,"askSize":13,"bidPrice":202.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.030053,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778544000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":201.55,"dividendRate":0.033238,"preHourTrading":{"tag":"盘前","latestPrice":201.3,"preClose":201.55,"latestTime":"09:28 EDT","volume":3964,"amount":798852.94872,"timestamp":1778506095165,"change":-0.25,"changeRate":-0.00124,"amplitude":0.007536},"postHourTrading":{"tag":"盘后","latestPrice":202.99,"preClose":202.78,"latestTime":"18:24 EDT","volume":688608,"amount":139635854.49311998,"timestamp":1778538268858,"change":0.21,"changeRate":0.001036,"amplitude":0.006953},"volumeRatio":0.829251,"impliedVol":0.2233,"impliedVolPercentile":0.0677},"requestUrl":"/m/hq/s/ABBV/tweets","defaultTab":"tweets","newsList":[{"id":"2631560116","title":"艾伯维(ABBV.US)乌帕替尼斑秃适应症已向美国FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560116","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631560116?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:40","pubTimestamp":1777452029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月28日，艾伯维宣布，已向美国FDA递交乌帕替尼的新适应症上市申请，用于治疗成人和12岁及以上青少年重度斑秃。乌帕替尼是艾伯维研发的一款口服、高选择性JAK1抑制剂，目前正在多种免疫介导性疾病中对其进行研究。乌帕替尼于2019年首次在美国获批上市，2022年2月获批进入中国。艾伯维表示，乌帕替尼正在针对斑秃、化脓性汗腺炎、大动脉炎、系统性红斑狼疮及白癜风开展III期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0820561909.HKD","LU2112291526.USD","LU0069063385.USD","LU2357627491.SGD","IE000BZT7R73.USD","LU0511384066.AUD","IE00BVYPNW00.USD","IPOS","LU0289739699.SGD","LU1291159041.SGD","LU0432979614.USD","LU1003077747.HKD","LU0256863902.USD","LU0256863811.USD","BK4139","IE00B42XCP33.USD","LU0949170772.SGD","LU1496350502.SGD","LU0211327993.USD","IE0009355771.USD","LU1267930573.SGD","LU0310800379.SGD","IE00BSNM7G36.USD","IE0004445239.USD","LU2129689431.USD","LU1267930490.SGD","LU0689472784.USD","IE00BJJMRZ35.SGD","LU0029864427.USD","LU0211328371.USD","LU1074936037.SGD","LU0128525929.USD","LU2237443465.HKD","LU0289961442.SGD","LU1244550221.USD","SG9999001440.SGD","SG9999003800.SGD","LU2023251221.USD","SG9999015952.SGD","LU2468319806.SGD","LU2089284900.SGD","IE000SO60NU8.SGD","LU1244550577.SGD","ABBV","LU0795875169.SGD","LU0965509101.SGD","LABU","BK4581","IE000MB6IJN5.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103715471","title":"艾伯维向FDA提交乌帕替尼治疗重度斑秃成人与青少年患者的新适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1103715471","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103715471?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:03","pubTimestamp":1777377803,"startTime":"0","endTime":"0","summary":"艾伯维公司已正式向美国食品药品监督管理局提交乌帕替尼（商品名：Rinvoq®）的新适应症申请，寻求批准该药物用于治疗成人和青少年重度斑秃患者。\n此次申报标志着JAK抑制剂在自身免疫性皮肤病治疗领域的重要拓展。若获批准，乌帕替尼将成为该疾病领域首个适用于青少年群体的靶向治疗选择，为深受斑秃困扰的患者提供新的治疗希望。\n临床研究数据显示，乌帕替尼在促进毛发再生方面展现出显著疗效。其作用机制通过选择性抑制JAK通路，有效阻断导致毛囊炎症的关键细胞因子信号传导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089284900.SGD","IE00B19Z3581.USD","LU0708994859.HKD","LU1989772923.USD","SG9999011175.SGD","LU0868494617.USD","LU1162221912.USD","LU1061106388.HKD","LU0203347892.USD","LU1244550221.USD","BK4581","LU0965508806.USD","LU0689472784.USD","LU1037948541.HKD","LU1291159041.SGD","IE000MB6IJN5.SGD","IE00BJT1NW94.SGD","IE000SO60NU8.SGD","IE00BLSP4239.USD","LU1093756325.SGD","LU1732800096.USD","LU2112291526.USD","LU0942090050.USD","LU2129689514.USD","LU0689626769.HKD","LU0417517546.SGD","LU0124676726.USD","LU1093756168.USD","LU1551013342.USD","LU1718418525.SGD","LU1934455194.USD","LU0511384066.AUD","LU0859254822.USD","BK4550","LU2087621335.USD","LU0057025933.USD","BK4566","SG9999003800.SGD","LU0256863902.USD","IE00BN8TJ469.HKD","LU1585245621.USD","LU0456855351.SGD","SG9999015978.USD","LU0882574055.USD","LU0965509283.SGD","IE00B42XCP33.USD","LU0211327993.USD","LU1496350502.SGD","LU0128525929.USD","LU0472753341.HKD","LU2129689605.HKD","LU0965509101.SGD","IE00BVYPNV92.GBP","LU1983299246.USD","BK4139","LU0820561818.USD","IE00BJJMRZ35.SGD","LU0795875169.SGD","IE00B19Z3B42.SGD","LU0256863811.USD","LU0861579265.USD","LU1551013425.SGD","IE000WAW04H5.SGD","LU0949170772.SGD","IE00B4R5TH58.HKD","BK4534","LU1839511570.USD","SG9999015986.USD","BK4585","LU1267930490.SGD","LU1430594728.SGD","LU2237443549.SGD","IE00BLSP4452.SGD","IE00BDGV0183.EUR","LU1074936037.SGD","IE0002141913.USD","LU2237443622.USD","IE000F7OJYX1.SGD","IE00B2B36J28.USD","LU0553294199.USD","LU1934455863.HKD","LU1003077747.HKD","SG9999001440.SGD","LU1023059063.AUD","LU2089283258.USD","LU1934455277.USD","LU2237443895.HKD","LU0310800379.SGD","LU1989772840.SGD","LU0029864427.USD","LU2237443465.HKD","LU0820561909.HKD","ABBV","IE00BFTCPJ56.SGD","LU0158827948.USD","IE00B3PB1722.GBP","IE00BBT3K403.USD","LU0122379950.USD","LU0661504455.SGD","LU2133065610.SGD","IE00BSNM7G36.USD","LU0203345920.USD","LU0965509010.AUD","LU0868494708.USD","BK4588","LU0823416689.USD","LU2347655156.SGD","IE0004445239.USD","LU1929549753.HKD","LU2237443382.USD","LU0211328371.USD","LU1732799900.SGD","SG9999015945.SGD","LU0943347566.SGD","LU2023251221.USD","LU0738911758.USD","LU1496350171.SGD","SG9999015952.SGD","LU0289739343.SGD","LU1244550577.SGD","LU0234570918.USD","LU0234572021.USD","LU1037948897.HKD","LU0432979614.USD","LU0545039389.USD","IE0002270589.USD","LU0114720955.EUR","LU0912757837.SGD","LU2129689431.USD","LU2237443978.SGD","LU0289739699.SGD","LU0170899867.USD","LU1989771016.USD","LU0198837287.USD","IE0000B7K699.USD","LU2357627491.SGD","LU0058720904.USD","LU0320765646.SGD","LU1267930573.SGD","LU2089984988.USD","LU1244550494.USD","IE0009355771.USD","IE000BZT7R73.USD","BK4559","BK4533","LU1057294990.SGD","IE00BGHQF631.EUR","LU0985320562.USD","IE00BVYPNW00.USD","LU0795875086.SGD","LU2468319806.SGD","LU0069063385.USD","LU0310799852.SGD","LU0289961442.SGD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148221705","title":"艾伯维Rinvoq在12周疗效评估中展现优于Humira的低疾病活动度和缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1148221705","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148221705?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:06","pubTimestamp":1777374363,"startTime":"0","endTime":"0","summary":"艾伯维公司旗下药物Rinvoq在治疗类风湿关节炎的12周关键节点评估中，其诱导低疾病活动度及临床缓解的效果显著优于对照药物Humira。临床数据显示，接受Rinvoq治疗的患者组在疾病活动指数评分、关节肿胀压痛计数等核心指标上均取得更具统计学意义的改善。这一结果进一步巩固了Rinvoq作为中重度活动性类风湿关节炎患者重要治疗选择的临床地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000WAW04H5.SGD","LU0795875169.SGD","LU0029864427.USD","LU1934455194.USD","IE00BVYPNW00.USD","LU0158827948.USD","LU0689472784.USD","IE000F7OJYX1.SGD","LU2237443895.HKD","LU0823416689.USD","LU0069063385.USD","LU1551013425.SGD","LU0170899867.USD","IE00BGHQF631.EUR","LU0868494617.USD","LU0417517546.SGD","IE0002141913.USD","IE00BBT3K403.USD","LU0057025933.USD","LU2129689514.USD","LU1267930490.SGD","IE000BZT7R73.USD","LU0289961442.SGD","LU1093756168.USD","LU1093756325.SGD","SG9999015978.USD","LU0128525929.USD","SG9999003800.SGD","BK4581","LU0511384066.AUD","LU0965509010.AUD","ABBV","LU0122379950.USD","LU2237443622.USD","LU1023059063.AUD","LU2112291526.USD","LU0545039389.USD","LU0795875086.SGD","IE00B19Z3B42.SGD","BK4585","SG9999011175.SGD","LU0661504455.SGD","IE00B42XCP33.USD","LU1732799900.SGD","IE00BSNM7G36.USD","LU0211328371.USD","LU2347655156.SGD","LU0912757837.SGD","LU0868494708.USD","LU1934455863.HKD","LU0861579265.USD","LU1983299246.USD","LU2237443549.SGD","LU1585245621.USD","LU0058720904.USD","LU1718418525.SGD","IE00BLSP4452.SGD","LU1037948897.HKD","LU1989772923.USD","LU0098860793.USD","LU0211327993.USD","LU1291159041.SGD","LU0310800379.SGD","LU0289739343.SGD","LU1934455277.USD","LU1839511570.USD","BK4534","IE00BDGV0183.EUR","LU0965509283.SGD","LU2089984988.USD","LU2237443465.HKD","IE00B2B36J28.USD","LU0203345920.USD","IE00BJT1NW94.SGD","LU0882574055.USD","LU1496350502.SGD","LU0198837287.USD","LU0985320562.USD","LU2237443382.USD","LU0965509101.SGD","IE00B4R5TH58.HKD","LU0472753341.HKD","LU2357627491.SGD","BK4533","LU0708994859.HKD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1061106388.HKD","SG9999015952.SGD","IE00BJJMRZ35.SGD","IE00BN8TJ469.HKD","LU1003077747.HKD","LU1732800096.USD","LU2023251221.USD","LU0689626769.HKD","LU2129689431.USD","LU1929549753.HKD","LU0432979614.USD","LU0256863902.USD","LU1162221912.USD","LU0124676726.USD","LU0203347892.USD","LU2237443978.SGD","BK4139","LU0738911758.USD","LU2087621335.USD","LU2089283258.USD","IE000MB6IJN5.SGD","SG9999015945.SGD","IE00B19Z3581.USD","IE00BVYPNV92.GBP","LU2133065610.SGD","LU0859254822.USD","LU1496350171.SGD","BK4588","IE00BLSP4239.USD","SG9999001440.SGD","LU0289739699.SGD","LU1244550221.USD","LU0943347566.SGD","LU1244550494.USD","LU1244550577.SGD","LU0234572021.USD","IE0009355771.USD","LU0320765646.SGD","LU2129689605.HKD","LU1267930573.SGD","IE00B3PB1722.GBP","LU1989772840.SGD","BK4550","LU1074936037.SGD","LU0234570918.USD","BK4566","LU0456855351.SGD","LU0553294199.USD","LU1037948541.HKD","LU0820561818.USD","LU0310799852.SGD","LU0942090050.USD","LU1057294990.SGD","LU0114720955.EUR","LU0965508806.USD","SG9999015986.USD","LU0820561909.HKD","LU1989771016.USD","IE0000B7K699.USD","LU0949170772.SGD","LU2468319806.SGD","BK4559","LU1551013342.USD","IE000SO60NU8.SGD","IE0004445239.USD","IE0002270589.USD","LU2089284900.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140955338","title":"Evolveimmune Therapeutics达成临床前里程碑 触发艾伯维1800万美元付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1140955338","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140955338?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374151,"startTime":"0","endTime":"0","summary":"生物技术公司Evolveimmune Therapeutics近日宣布，其研发项目成功达到关键临床前里程碑。这一重要进展触发了与艾伯维公司合作协议中的付款条款。\n根据双方既定协议，艾伯维将向Evolveimmune支付高达1800万美元的里程碑款项。该笔资金将用于支持后续研发工作的持续推进。\n此次里程碑的达成，标志着双方合作项目取得了实质性突破。这不仅验证了Evolveimmune技术平台的有效性，也为项目向临床阶段推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","LU0553294199.USD","LU2112291526.USD","LU1037948897.HKD","LU2468319806.SGD","LU1244550221.USD","SG9999003800.SGD","ABBV","IE00BN8TJ469.HKD","IE000SO60NU8.SGD","IE000WAW04H5.SGD","SG9999015945.SGD","IE0009355771.USD","LU1061106388.HKD","LU0432979614.USD","LU0289739343.SGD","LU0965508806.USD","LU0965509283.SGD","LU1496350502.SGD","LU1003077747.HKD","IE00BJJMRZ35.SGD","LU0868494708.USD","LU2237443382.USD","IE00BGHQF631.EUR","IE00B19Z3B42.SGD","BK4559","LU0211328371.USD","LU2237443465.HKD","LU0289739699.SGD","LU1732799900.SGD","SG9999011175.SGD","LU0211327993.USD","LU0868494617.USD","LU1093756325.SGD","LU0965509101.SGD","LU2089984988.USD","LU0170899867.USD","LU0158827948.USD","LU0949170772.SGD","LU0289961442.SGD","LU0661504455.SGD","IE0004445239.USD","LU1989772840.SGD","IE00BLSP4452.SGD","LU0689626769.HKD","SG9999015986.USD","LU0823416689.USD","LU1934455863.HKD","LU0738911758.USD","LU1989771016.USD","IE000F7OJYX1.SGD","LU2237443895.HKD","LU1718418525.SGD","LU0472753341.HKD","LU0057025933.USD","LU1585245621.USD","IE00BDGV0183.EUR","BK4534","IE00B3PB1722.GBP","LU1934455277.USD","LU1023059063.AUD","LU2129689514.USD","LU0029864427.USD","LU0069063385.USD","IE0000B7K699.USD","IE00BVYPNW00.USD","LU1929549753.HKD","IE000MB6IJN5.SGD","IE00BSNM7G36.USD","IE00B42XCP33.USD","LU2089284900.SGD","LU0882574055.USD","LU1551013425.SGD","IE00B4R5TH58.HKD","LU0256863902.USD","LU1496350171.SGD","LU1839511570.USD","BK4588","LU0114720955.EUR","SG9999015952.SGD","BK4585","LU1057294990.SGD","LU1093756168.USD","LU2357627491.SGD","LU1037948541.HKD","LU1244550494.USD","SG9999001440.SGD","LU1551013342.USD","LU0256863811.USD","LU0942090050.USD","LU2133065610.SGD","IE00B19Z3581.USD","IE00BVYPNV92.GBP","LU0795875086.SGD","BK4533","IE000BZT7R73.USD","LU0545039389.USD","IE00BBT3K403.USD","LU0417517546.SGD","LU1934455194.USD","LU2129689605.HKD","LU0820561909.HKD","LU2089283258.USD","LU2237443978.SGD","LU1732800096.USD","LU1291159041.SGD","LU2347655156.SGD","LU1074936037.SGD","LU0098860793.USD","LU0820561818.USD","LU0234570918.USD","LU1989772923.USD","LU0124676726.USD","LU2087621335.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU1267930490.SGD","LU0943347566.SGD","BK4139","LU0912757837.SGD","BK4550","LU1162221912.USD","LU0122379950.USD","IE00B2B36J28.USD","LU0203347892.USD","LU0128525929.USD","LU0058720904.USD","LU1983299246.USD","LU0234572021.USD","LU2023251221.USD","LU0310799852.SGD","LU0985320562.USD","LU0965509010.AUD","LU0310800379.SGD","LU2237443622.USD","LU0320765646.SGD","LU2237443549.SGD","LU0861579265.USD","IE00BLSP4239.USD","BK4566","LU1244550577.SGD","IE0002270589.USD","LU0511384066.AUD","LU1430594728.SGD","BK4581","LU1267930573.SGD","LU0198837287.USD","IE00BFTCPJ56.SGD","SG9999015978.USD","IE0002141913.USD","LU0203345920.USD","LU2129689431.USD","LU0708994859.HKD","LU0689472784.USD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144855855","title":"Evolveimmune Therapeutics与艾伯维合作达成临床前研究里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1144855855","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144855855?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374151,"startTime":"0","endTime":"0","summary":"生物技术公司Evolveimmune Therapeutics宣布，其与全球生物制药巨头艾伯维公司的合作项目已成功实现关键临床前研究里程碑。这一进展标志着双方在创新疗法开发领域取得实质性突破，为后续临床研究奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU1037948541.HKD","LU1934455194.USD","LU1989772840.SGD","SG9999015952.SGD","LU0823416689.USD","LU2129689605.HKD","LU1496350502.SGD","LU1732799900.SGD","LU1061106388.HKD","LU0511384066.AUD","IE00BLSP4239.USD","LU2089984988.USD","SG9999015986.USD","LU0310800379.SGD","LU2112291526.USD","LU1551013425.SGD","IE00BLSP4452.SGD","LU0545039389.USD","LU1839511570.USD","LU0942090050.USD","IE000BZT7R73.USD","LU0234570918.USD","LU0198837287.USD","LU0689626769.HKD","LU2023251221.USD","IE00BN8TJ469.HKD","LU0289739343.SGD","LU0456855351.SGD","LU0310799852.SGD","BK4585","LU0234572021.USD","LU2347655156.SGD","SG9999015945.SGD","LU0170899867.USD","LU2357627491.SGD","IE00BBT3K403.USD","LU1037948897.HKD","LU0912757837.SGD","LU1983299246.USD","LU2129689431.USD","LU2089284900.SGD","IE0000B7K699.USD","LU0256863811.USD","LU1093756168.USD","BK4533","LU0965509101.SGD","LU0289739699.SGD","LU1074936037.SGD","LU2237443895.HKD","LU1244550221.USD","LU0211327993.USD","IE00B2B36J28.USD","LU1585245621.USD","IE00B3PB1722.GBP","IE0002270589.USD","SG9999015978.USD","IE00B19Z3B42.SGD","LU1718418525.SGD","IE00B19Z3581.USD","IE0002141913.USD","LU0057025933.USD","IE00BSNM7G36.USD","LU0203347892.USD","LU0417517546.SGD","LU2129689514.USD","IE0009355771.USD","IE00BVYPNV92.GBP","LU2087621335.USD","IE000WAW04H5.SGD","LU1244550577.SGD","LU0158827948.USD","LU0965509010.AUD","LU1057294990.SGD","BK4534","LU1934455277.USD","LU1162221912.USD","SG9999003800.SGD","LU0661504455.SGD","LU1003077747.HKD","BK4566","IE000SO60NU8.SGD","LU0128525929.USD","LU0985320562.USD","LU1093756325.SGD","LU1291159041.SGD","LU1929549753.HKD","LU0965508806.USD","LU0795875086.SGD","LU2237443382.USD","LU2237443978.SGD","LU0868494708.USD","LU1551013342.USD","LU1989772923.USD","LU0256863902.USD","LU2237443549.SGD","LU0820561909.HKD","LU0211328371.USD","IE0004445239.USD","LU0795875169.SGD","LU0203345920.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0289961442.SGD","LU1934455863.HKD","LU1989771016.USD","IE00BDGV0183.EUR","LU0124676726.USD","BK4559","BK4550","LU1732800096.USD","BK4139","LU1496350171.SGD","LU0058720904.USD","IE00B42XCP33.USD","LU1430594728.SGD","LU0114720955.EUR","LU0122379950.USD","LU1267930573.SGD","SG9999001440.SGD","IE000F7OJYX1.SGD","LU1244550494.USD","IE00BFTCPJ56.SGD","LU0689472784.USD","LU0738911758.USD","LU2237443465.HKD","IE000MB6IJN5.SGD","LU0098860793.USD","IE00BVYPNW00.USD","BK4581","LU2237443622.USD","LU0882574055.USD","LU0861579265.USD","LU0029864427.USD","LU0320765646.SGD","LU2133065610.SGD","LU0472753341.HKD","LU0553294199.USD","LU2468319806.SGD","ABBV","LU0708994859.HKD","SG9999011175.SGD","LU0069063385.USD","LU2089283258.USD","LU0820561818.USD","LU1267930490.SGD","BK4588","LU0943347566.SGD","LU0859254822.USD","LU0868494617.USD","IE00BGHQF631.EUR","IE00BJT1NW94.SGD","LU0965509283.SGD","LU0949170772.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190294448","title":"Rinvoq® (乌帕替尼) 在对首个TNF抑制剂应答不佳的类风湿关节炎患者头对头研究中，主要终点指标表现优于Humira® (阿达木单抗)","url":"https://stock-news.laohu8.com/highlight/detail?id=1190294448","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190294448?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374131,"startTime":"0","endTime":"0","summary":"在一项针对首个肿瘤坏死因子(TNF)抑制剂治疗失败后的类风湿关节炎患者的头对头临床研究中，Rinvoq® (乌帕替尼) 在主要终点指标上表现出优于Humira® (阿达木单抗)的疗效。该研究结果凸显了乌帕替尼在此类患者群体中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0000B7K699.USD","LU2112291526.USD","LU2357627491.SGD","LU0689626769.HKD","LU1003077747.HKD","LU1093756168.USD","BK4585","LU0949170772.SGD","LU0965509010.AUD","LU2087621335.USD","IE00BDGV0183.EUR","LU2237443895.HKD","IE00B19Z3B42.SGD","IE0009355771.USD","SG9999015945.SGD","LU0203347892.USD","LU2089283258.USD","IE00B3PB1722.GBP","LU1267930573.SGD","LU0738911758.USD","LU0912757837.SGD","LU0158827948.USD","IE0002270589.USD","IE00B19Z3581.USD","LU0170899867.USD","LU2129689605.HKD","IE000F7OJYX1.SGD","IE00B4R5TH58.HKD","LU2468319806.SGD","LU0985320562.USD","BK4534","LU1057294990.SGD","IE000SO60NU8.SGD","LU1162221912.USD","LU0795875169.SGD","LU0861579265.USD","LU0545039389.USD","BK4581","IE00BGHQF631.EUR","LU1929549753.HKD","LU2237443622.USD","LU0820561909.HKD","LU0868494708.USD","LU2237443978.SGD","LU1244550494.USD","LU1037948541.HKD","SG9999015986.USD","LU0661504455.SGD","LU0417517546.SGD","LU0211327993.USD","BK4559","IE00BBT3K403.USD","LU0289739343.SGD","LU0310800379.SGD","IE0004445239.USD","LU2237443382.USD","IE00BJJMRZ35.SGD","LU1839511570.USD","LU1989771016.USD","LU1074936037.SGD","LU0124676726.USD","LU0128525929.USD","LU1585245621.USD","LU0234570918.USD","SG9999011175.SGD","LU1430594728.SGD","LU0868494617.USD","LU1093756325.SGD","LU2023251221.USD","LU2089284900.SGD","SG9999015978.USD","LU2133065610.SGD","LU0114720955.EUR","LU0310799852.SGD","LU1037948897.HKD","LU0882574055.USD","LU0859254822.USD","LU0823416689.USD","LU1551013342.USD","LU0069063385.USD","IE000BZT7R73.USD","BK4588","IE00BVYPNW00.USD","LU0511384066.AUD","LU0553294199.USD","LU0256863902.USD","LU0057025933.USD","LU0472753341.HKD","LU0203345920.USD","IE00BVYPNV92.GBP","IE00B42XCP33.USD","IE00BN8TJ469.HKD","IE00B2B36J28.USD","LU2347655156.SGD","LU1718418525.SGD","LU0795875086.SGD","LU0234572021.USD","LU0820561818.USD","LU2129689431.USD","IE00BSNM7G36.USD","LU1732800096.USD","IE00BFTCPJ56.SGD","LU2129689514.USD","LU0098860793.USD","LU0029864427.USD","LU0965509283.SGD","LU0211328371.USD","LU2237443465.HKD","LU2089984988.USD","LU1023059063.AUD","LU1244550221.USD","LU1551013425.SGD","SG9999015952.SGD","BK4550","LU0965508806.USD","IE00BLSP4452.SGD","LU1989772923.USD","ABBV","LU0320765646.SGD","LU0198837287.USD","LU0456855351.SGD","LU0289739699.SGD","LU1061106388.HKD","LU0432979614.USD","LU1291159041.SGD","IE00BLSP4239.USD","LU0256863811.USD","LU0942090050.USD","BK4139","IE000WAW04H5.SGD","LU1496350502.SGD","LU1983299246.USD","IE0002141913.USD","LU1267930490.SGD","BK4566","LU0689472784.USD","LU1934455277.USD","LU1989772840.SGD","LU0289961442.SGD","BK4533","LU2237443549.SGD","SG9999001440.SGD","SG9999003800.SGD","LU1732799900.SGD","LU0943347566.SGD","LU0122379950.USD","LU1244550577.SGD","IE00BJT1NW94.SGD","LU0708994859.HKD","LU0965509101.SGD","LU0058720904.USD","LU1934455863.HKD","LU1934455194.USD","IE000MB6IJN5.SGD","LU1496350171.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187354202","title":"艾伯维向FDA提交Skyrizi®用于中重度活动性克罗恩病成人患者皮下诱导治疗的监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1187354202","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187354202?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:18","pubTimestamp":1777292296,"startTime":"0","endTime":"0","summary":"生物制药巨头艾伯维公司已正式向美国食品药品监督管理局（FDA）提交监管申请，寻求批准其创新药物Skyrizi®（risankizumab-rzaa）用于中重度活动性克罗恩病成人患者的皮下诱导治疗方案。此次申请标志着该药物在拓展胃肠道疾病治疗适应症方面迈出关键一步，有望为克罗恩病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1496350171.SGD","LU1496350502.SGD","LU2089984988.USD","LU1929549753.HKD","LU0122379950.USD","LU2129689605.HKD","LU0795875169.SGD","LU2112291526.USD","LU1037948897.HKD","IE0004445239.USD","LU0868494708.USD","LU2237443895.HKD","LU1718418525.SGD","LU0820561909.HKD","LU0689626769.HKD","IE00B2B36J28.USD","IE00BGHQF631.EUR","IE00BLSP4452.SGD","LU0456855351.SGD","LU2237443978.SGD","LU0057025933.USD","BK4533","LU1732800096.USD","LU0859254822.USD","LU0861579265.USD","BK4588","LU1934455194.USD","SG9999015952.SGD","LU0114720955.EUR","LU0868494617.USD","BK4559","LU0211327993.USD","LU0158827948.USD","LU1989772840.SGD","LU2089283258.USD","LU0289739699.SGD","SG9999015986.USD","IE00BSNM7G36.USD","LU1839511570.USD","LU2237443382.USD","LU2089284900.SGD","LU2129689514.USD","LU0965509283.SGD","LU0823416689.USD","LU1430594728.SGD","SG9999015978.USD","LU1061106388.HKD","LU0203345920.USD","LU1732799900.SGD","LU1551013342.USD","LU0029864427.USD","LU1551013425.SGD","LU2347655156.SGD","LU0234572021.USD","LU0256863811.USD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU1934455863.HKD","IE00BVYPNV92.GBP","LU1244550494.USD","LU1989772923.USD","BK4139","LU0882574055.USD","SG9999001440.SGD","LU0310799852.SGD","LU1267930573.SGD","LU0098860793.USD","LU2133065610.SGD","LU0942090050.USD","LU0320765646.SGD","LU2023251221.USD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B42XCP33.USD","LU1934455277.USD","LU0310800379.SGD","LU0661504455.SGD","LU0553294199.USD","IE00BJT1NW94.SGD","IE0000B7K699.USD","IE00B4R5TH58.HKD","LU1267930490.SGD","BK4581","LU0069063385.USD","LU0965509010.AUD","LU0965509101.SGD","LU0211328371.USD","IE000SO60NU8.SGD","LU2357627491.SGD","IE00B19Z3581.USD","LU0234570918.USD","LU0912757837.SGD","LU0689472784.USD","SG9999003800.SGD","SG9999015945.SGD","LU0203347892.USD","LU0708994859.HKD","IE0009355771.USD","LU1989771016.USD","LU1057294990.SGD","BK4534","IE000MB6IJN5.SGD","LU0820561818.USD","LU0432979614.USD","LU0198837287.USD","LU2468319806.SGD","LU2237443549.SGD","LU1023059063.AUD","LU2087621335.USD","LU0965508806.USD","LU1244550577.SGD","LU2237443622.USD","LU0472753341.HKD","IE000BZT7R73.USD","LU0170899867.USD","LU0985320562.USD","LU0289739343.SGD","LU0128525929.USD","BK4550","LU0949170772.SGD","LU1585245621.USD","IE00BLSP4239.USD","ABBV","SG9999011175.SGD","IE000WAW04H5.SGD","LU1003077747.HKD","LU1983299246.USD","LU0058720904.USD","LU0943347566.SGD","LU0738911758.USD","LU0256863902.USD","LU0289961442.SGD","IE00B3PB1722.GBP","LU0545039389.USD","LU1074936037.SGD","LU1244550221.USD","IE00BDGV0183.EUR","BK4585","LU1037948541.HKD","LU0795875086.SGD","LU0124676726.USD","IE00BFTCPJ56.SGD","LU1162221912.USD","IE000F7OJYX1.SGD","BK4566","LU1093756168.USD","LU2129689431.USD","LU2237443465.HKD","IE00BN8TJ469.HKD","LU0417517546.SGD","LU0511384066.AUD","IE0002141913.USD","LU1291159041.SGD","IE00BVYPNW00.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166311849","title":"财报前瞻｜艾伯维公司本季度营收预计增13.93%，机构观点偏空","url":"https://stock-news.laohu8.com/highlight/detail?id=1166311849","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166311849?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:02","pubTimestamp":1776816149,"startTime":"0","endTime":"0","summary":"艾伯维公司计划于2026年04月29日美股盘前发布最新季度业绩，市场聚焦增长动能与利润弹性。上季度艾伯维公司实现营收166.18亿美元，同比增长10.04%；毛利率72.61%；归属于母公司股东的净利润18.16亿美元，净利率10.93%；调整后每股收益2.71美元，同比增长25.46%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜艾伯维公司本季度营收预计增13.93%，机构观点偏空","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137791418","title":"Collplant计划开发新型再生真皮与软组织填充剂产品组合，目标两年内启动临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1137791418","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137791418?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078204,"startTime":"0","endTime":"0","summary":"Collplant公司近日宣布，将着手开发一系列创新的再生真皮与软组织填充剂新产品组合。该公司明确表示，计划在未来两年内正式启动相关临床实验，以验证其安全性与有效性。这一战略布局旨在拓展其在再生医学领域的产品管线，为市场带来更先进的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU1989771016.USD","LU2089984988.USD","IE0002141913.USD","BK4533","LU1061106388.HKD","LU2129689514.USD","LU1093756168.USD","LU0456855351.SGD","IE0004445239.USD","LU0289739343.SGD","BK4139","LU0289739699.SGD","LU0029864427.USD","LU1093756325.SGD","SG9999001440.SGD","SG9999015952.SGD","LU1929549753.HKD","LU0069063385.USD","IE000SO60NU8.SGD","LU0823416689.USD","LU0320765646.SGD","IE00BVYPNV92.GBP","LU1934455863.HKD","LU1989772840.SGD","LU2089283258.USD","LU2112291526.USD","LU0689472784.USD","IE00B42XCP33.USD","LU2237443465.HKD","LU0965509283.SGD","LU1267930573.SGD","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU0234570918.USD","LU0738911758.USD","IE00B2B36J28.USD","LU0310800379.SGD","LU2347655156.SGD","BK4566","LU1003077747.HKD","IE00BGHQF631.EUR","LU0943347566.SGD","LU1551013342.USD","IE00BDGV0183.EUR","LU0417517546.SGD","LU0211327993.USD","LU2237443622.USD","LU1162221912.USD","LU0965509101.SGD","LU2129689605.HKD","LU2133065610.SGD","LU1585245621.USD","LU0158827948.USD","LU1430594728.SGD","SG9999015945.SGD","LU0203347892.USD","LU0868494617.USD","IE000F7OJYX1.SGD","LU2237443549.SGD","LU2237443978.SGD","LU0689626769.HKD","IE0000B7K699.USD","SG9999015986.USD","LU1496350502.SGD","LU0432979614.USD","LU0124676726.USD","LU0198837287.USD","LU0472753341.HKD","LU0820561818.USD","LU1732800096.USD","LU2237443895.HKD","LU0256863902.USD","BK4581","BK4550","BK4559","LU1244550494.USD","LU0122379950.USD","LU0912757837.SGD","LU1291159041.SGD","LU1983299246.USD","LU0256863811.USD","LU0289961442.SGD","LU1732799900.SGD","LU0211328371.USD","LU0553294199.USD","LU0203345920.USD","LU0234572021.USD","BK4588","LU0661504455.SGD","IE00B19Z3B42.SGD","LU0708994859.HKD","IE00B3PB1722.GBP","LU0170899867.USD","LU0058720904.USD","LU1037948897.HKD","LU0882574055.USD","IE000BZT7R73.USD","LU0861579265.USD","LU2089284900.SGD","LU0820561909.HKD","LU0310799852.SGD","IE000MB6IJN5.SGD","LU1244550221.USD","LU1718418525.SGD","LU1934455194.USD","LU2129689431.USD","IE0009355771.USD","LU0511384066.AUD","LU0965509010.AUD","IE00BJJMRZ35.SGD","LU0985320562.USD","LU1934455277.USD","IE00BLSP4452.SGD","LU1037948541.HKD","IE00BVYPNW00.USD","SG9999011175.SGD","LU0949170772.SGD","LU1244550577.SGD","IE00BSNM7G36.USD","IE000WAW04H5.SGD","LU0795875086.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1074936037.SGD","LU0965508806.USD","BK4585","LU1023059063.AUD","IE00BLSP4239.USD","LU1551013425.SGD","LU1057294990.SGD","LU1989772923.USD","ABBV","IE00BBT3K403.USD","IE00BJT1NW94.SGD","LU2237443382.USD","LU0868494708.USD","LU1496350171.SGD","SG9999003800.SGD","LU0098860793.USD","LU2087621335.USD","LU2468319806.SGD","LU0057025933.USD","LU0545039389.USD","LU0128525929.USD","BK4534","SG9999015978.USD","IE00BN8TJ469.HKD","LU2023251221.USD","LU0942090050.USD","LU1267930490.SGD","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139488426","title":"艾尔建工业公司行使权利终止与Collplant Biotechnologies Ltd的开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1139488426","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139488426?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078197,"startTime":"0","endTime":"0","summary":"艾尔建工业公司已正式行使其权利，终止了与Collplant Biotechnologies Ltd之间原有的开发合作协议。这一决定标志着双方在相关技术领域的合作暂时告一段落。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863902.USD","LU0553294199.USD","LU0098860793.USD","SG9999015986.USD","LU2023251221.USD","LU1023059063.AUD","LU0124676726.USD","LU1934455194.USD","LU0545039389.USD","LU0868494708.USD","LU0861579265.USD","LU1551013425.SGD","LU0256863811.USD","LU0057025933.USD","IE0000B7K699.USD","BK4585","IE000BZT7R73.USD","LU0689626769.HKD","LU0511384066.AUD","LU1989772923.USD","LU0158827948.USD","LU0949170772.SGD","LU0170899867.USD","LU2347655156.SGD","IE00BBT3K403.USD","LU1162221912.USD","LU1244550577.SGD","LU0472753341.HKD","LU0942090050.USD","LU1839511570.USD","LU0456855351.SGD","LU0289739699.SGD","LU1929549753.HKD","BK4588","SG9999015952.SGD","LU1291159041.SGD","IE00B19Z3581.USD","IE0002141913.USD","IE000WAW04H5.SGD","LU1093756325.SGD","LU1244550494.USD","SG9999001440.SGD","IE0002270589.USD","LU0211327993.USD","LU1983299246.USD","LU1037948897.HKD","LU0965508806.USD","BK4533","IE00BVYPNW00.USD","BK4550","LU0965509101.SGD","LU2237443382.USD","LU0820561818.USD","IE00BDGV0183.EUR","LU0943347566.SGD","IE00B42XCP33.USD","LU0029864427.USD","LU0234570918.USD","LU0234572021.USD","LU0114720955.EUR","LU0965509010.AUD","IE00BVYPNV92.GBP","IE0009355771.USD","LU0738911758.USD","LU1732800096.USD","IE00BFTCPJ56.SGD","SG9999011175.SGD","LU1267930490.SGD","LU1074936037.SGD","LU0417517546.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","SG9999015945.SGD","IE00B19Z3B42.SGD","IE00B3PB1722.GBP","BK4566","LU0320765646.SGD","LU2237443465.HKD","BK4534","IE00BGHQF631.EUR","IE00BSNM7G36.USD","LU0795875169.SGD","LU2087621335.USD","LU2133065610.SGD","SG9999003800.SGD","LU1585245621.USD","LU0882574055.USD","LU2237443622.USD","LU1430594728.SGD","LU0795875086.SGD","IE00BLSP4452.SGD","SG9999015978.USD","IE00BN8TJ469.HKD","IE000F7OJYX1.SGD","LU1551013342.USD","LU0310800379.SGD","LU1093756168.USD","LU0310799852.SGD","LU1732799900.SGD","IE000SO60NU8.SGD","LU1989771016.USD","LU0058720904.USD","LU0985320562.USD","LU1037948541.HKD","LU0912757837.SGD","IE00B2B36J28.USD","LU2129689431.USD","LU2089284900.SGD","BK4559","LU0868494617.USD","LU0661504455.SGD","BK4581","LU1496350502.SGD","LU1934455277.USD","IE000MB6IJN5.SGD","LU2089984988.USD","BK4139","LU0203345920.USD","LU0708994859.HKD","LU0211328371.USD","LU2089283258.USD","LU0122379950.USD","LU1496350171.SGD","LU0198837287.USD","LU0069063385.USD","LU0432979614.USD","LU0965509283.SGD","LU0820561909.HKD","LU1718418525.SGD","LU1267930573.SGD","LU1061106388.HKD","LU0289961442.SGD","LU1057294990.SGD","LU2129689605.HKD","LU2112291526.USD","LU1003077747.HKD","LU2237443549.SGD","IE0004445239.USD","ABBV","IE00BLSP4239.USD","LU1989772840.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU2129689514.USD","LU0128525929.USD","LU0203347892.USD","LU1244550221.USD","LU0689472784.USD","LU2237443978.SGD","LU0823416689.USD","LU2237443895.HKD","LU1934455863.HKD","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165970887","title":"海思科将获3000万美元首付款，潜在里程碑付款最高可达7.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165970887","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165970887?lang=zh_cn&edition=full","pubTime":"2026-04-12 16:12","pubTimestamp":1775981533,"startTime":"0","endTime":"0","summary":"海思科医药集团宣布，公司将获得3000万美元的首付款，并有资格获得最高达7.15亿美元的潜在里程碑付款。此次交易涉及与艾伯维公司的合作协议，标志着海思科在创新药研发领域的重大进展。根据协议条款，海思科将负责特定研发项目的推进，而艾伯维公司将基于项目进展支付相应款项。这一合作不仅为海思科带来即时的资金支持，还为其长期发展提供了重要的财务保障。业界认为，此类高额里程碑付款安排，凸显了海思科研发能力的国际认可度，有望进一步提升其在全球医药市场的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","LU1551013425.SGD","LU1839511570.USD","LU2112291526.USD","LU0868494617.USD","LU1162221912.USD","LU1267930490.SGD","LU2237443622.USD","LU1074936037.SGD","LU1093756325.SGD","IE0000B7K699.USD","IE000BZT7R73.USD","SG9999015952.SGD","LU0553294199.USD","LU1037948541.HKD","LU2237443382.USD","LU1496350502.SGD","IE00BN8TJ469.HKD","LU0456855351.SGD","LU0170899867.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU1093756168.USD","IE00BLSP4239.USD","BK4566","IE000F7OJYX1.SGD","BK4581","LU2468319806.SGD","IE00B42XCP33.USD","LU1244550494.USD","SG9999015986.USD","IE0009355771.USD","LU0069063385.USD","LU0256863902.USD","IE00B19Z3581.USD","LU1934455863.HKD","LU2089284900.SGD","LU0158827948.USD","LU2237443978.SGD","LU0472753341.HKD","LU0949170772.SGD","LU1989772840.SGD","BK4139","LU0098860793.USD","LU1929549753.HKD","LU1718418525.SGD","IE000WAW04H5.SGD","LU2129689431.USD","BK4533","IE00BJT1NW94.SGD","LU0203347892.USD","ABBV","IE00BDGV0183.EUR","LU0795875086.SGD","LU0965509283.SGD","LU2237443895.HKD","IE0002141913.USD","LU2347655156.SGD","LU0198837287.USD","IE00BBT3K403.USD","LU0211328371.USD","LU0289739343.SGD","IE0002270589.USD","LU1430594728.SGD","LU2133065610.SGD","LU1585245621.USD","LU2129689605.HKD","LU1244550577.SGD","LU1732799900.SGD","LU0289739699.SGD","LU0289961442.SGD","LU1291159041.SGD","LU2087621335.USD","LU1244550221.USD","LU0234572021.USD","LU0861579265.USD","LU2023251221.USD","LU2237443465.HKD","LU0868494708.USD","LU0234570918.USD","LU0965509010.AUD","BK4585","SG9999015945.SGD","IE00B3PB1722.GBP","LU0820561909.HKD","LU0058720904.USD","LU0942090050.USD","IE00BSNM7G36.USD","IE0004445239.USD","LU0943347566.SGD","LU1732800096.USD","BK4550","BK0028","LU0965508806.USD","LU0545039389.USD","LU1003077747.HKD","LU1983299246.USD","LU0417517546.SGD","LU0965509101.SGD","SG9999015978.USD","IE000SO60NU8.SGD","LU0114720955.EUR","LU0882574055.USD","SG9999011175.SGD","BK0188","SG9999003800.SGD","LU0689626769.HKD","LU2237443549.SGD","LU0057025933.USD","LU1496350171.SGD","BK0033","LU0128525929.USD","LU0320765646.SGD","LU0738911758.USD","LU0310799852.SGD","LU1989771016.USD","LU0511384066.AUD","BK0077","IE00BGHQF631.EUR","LU1023059063.AUD","LU0029864427.USD","IE00BVYPNV92.GBP","LU1061106388.HKD","LU0122379950.USD","LU0310800379.SGD","LU0795875169.SGD","LU0203345920.USD","LU0820561818.USD","BK4559","LU2089984988.USD","LU0661504455.SGD","LU0689472784.USD","LU0211327993.USD","BK4534","LU1057294990.SGD","002653","LU1989772923.USD","IE000MB6IJN5.SGD","BK4588","LU2129689514.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU1551013342.USD","LU0985320562.USD","LU0432979614.USD","LU0708994859.HKD","LU0823416689.USD","LU2089283258.USD","BK0239","LU0912757837.SGD","IE00B4R5TH58.HKD","LU1934455194.USD","IE00BVYPNW00.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU1267930573.SGD","LU0124676726.USD","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169059527","title":"艾伯维公司：计入2026年第一季度收购IPR&D及里程碑费用影响后，2026年全年调整后稀释每股收益指引区间为13.96美元至14.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169059527","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169059527?lang=zh_cn&edition=full","pubTime":"2026-04-04 04:10","pubTimestamp":1775247012,"startTime":"0","endTime":"0","summary":"艾伯维公司公布了其2026年全年的财务指引。根据指引，在考虑了2026年第一季度发生的收购IPR&D（已获知识产权研发项目）及里程碑费用影响后，公司预计全年调整后的稀释每股收益将在13.96美元至14.16美元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0234572021.USD","LU1074936037.SGD","IE00B19Z3B42.SGD","IE0000B7K699.USD","IE00BJT1NW94.SGD","LU0949170772.SGD","LU0069063385.USD","LU0823416689.USD","LU2237443978.SGD","LU0289739343.SGD","BK4533","LU1061106388.HKD","LU0289961442.SGD","LU0943347566.SGD","IE000SO60NU8.SGD","LU1023059063.AUD","LU0553294199.USD","LU0256863902.USD","LU0417517546.SGD","LU0882574055.USD","LU0942090050.USD","LU1430594728.SGD","IE00BSNM7G36.USD","LU2129689605.HKD","IE00B3PB1722.GBP","SG9999015952.SGD","IE00B2B36J28.USD","LU0820561909.HKD","LU1989771016.USD","LU2237443549.SGD","LU1496350502.SGD","IE00B42XCP33.USD","IE00BFTCPJ56.SGD","SG9999011175.SGD","SG9999015978.USD","LU1162221912.USD","BK4550","IE00B4R5TH58.HKD","LU0965509010.AUD","LU0820561818.USD","LU1983299246.USD","LU0795875169.SGD","LU1929549753.HKD","IE000MB6IJN5.SGD","LU0098860793.USD","IE0009355771.USD","LU2129689514.USD","SG9999015986.USD","LU2237443622.USD","LU0708994859.HKD","LU1551013342.USD","LU0310800379.SGD","LU0912757837.SGD","LU1934455863.HKD","LU0661504455.SGD","LU0128525929.USD","LU0310799852.SGD","LU0861579265.USD","LU1585245621.USD","LU0029864427.USD","SG9999001440.SGD","LU0472753341.HKD","IE00BLSP4452.SGD","LU0211328371.USD","LU0965508806.USD","LU1037948897.HKD","BK4588","IE000F7OJYX1.SGD","LU1093756325.SGD","LU1244550494.USD","LU2347655156.SGD","IE00BBT3K403.USD","LU0689472784.USD","BK4585","IE000WAW04H5.SGD","IE00BGHQF631.EUR","LU0545039389.USD","LU2089984988.USD","IE00BN8TJ469.HKD","LU1989772840.SGD","LU0795875086.SGD","IE00B19Z3581.USD","LU1267930573.SGD","IE00BVYPNW00.USD","LU1003077747.HKD","LU0256863811.USD","LU0058720904.USD","LU1732800096.USD","LU2112291526.USD","IE0004445239.USD","LU0985320562.USD","LU0965509283.SGD","IE0002141913.USD","LU2089284900.SGD","LU1551013425.SGD","LU0965509101.SGD","LU0057025933.USD","LU0114720955.EUR","LU0198837287.USD","LU1989772923.USD","LU1244550577.SGD","LU0738911758.USD","LU0158827948.USD","LU1037948541.HKD","BK4559","LU2023251221.USD","LU2087621335.USD","BK4566","LU1244550221.USD","LU1934455277.USD","LU1732799900.SGD","LU0122379950.USD","LU1093756168.USD","LU2237443895.HKD","BK4581","LU2133065610.SGD","LU1934455194.USD","LU1839511570.USD","LU1267930490.SGD","IE0002270589.USD","LU1057294990.SGD","LU0289739699.SGD","IE00BLSP4239.USD","LU0211327993.USD","SG9999003800.SGD","BK4139","LU0868494708.USD","IE00BVYPNV92.GBP","LU0511384066.AUD","LU2468319806.SGD","LU1718418525.SGD","LU0868494617.USD","ABBV","LU2237443465.HKD","LU0689626769.HKD","LU0203347892.USD","LU2089283258.USD","IE000BZT7R73.USD","SG9999015945.SGD","LU0234570918.USD","IE00BDGV0183.EUR","LU0170899867.USD","LU2237443382.USD","LU1291159041.SGD","BK4534","LU1496350171.SGD","LU2129689431.USD","LU0456855351.SGD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU0320765646.SGD","LU0124676726.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620143022","title":"法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2620143022","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620143022?lang=zh_cn&edition=full","pubTime":"2026-03-19 14:55","pubTimestamp":1773903308,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，周三，艾伯维股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司与 Protagonist Therapeutics新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局已批准 Icotyde 上市。不过，泰指出，鉴于 Skyrizi 强大的疗效及其每季度一次的注射频率，艾伯维在斑块状银屑病领域仍处于有利地位。泰还提到，针对 Icotyde 在银屑病关节炎等其他炎症性疾病中的持续研究，她认为这“可能代表着对 Skyrizi 的额外竞争”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2471134523.USD","LU1934455277.USD","LU0114720955.EUR","LU0795875169.SGD","LU1496350502.SGD","LU0057025933.USD","LU0511384066.AUD","LU0289739699.SGD","LU1929549753.HKD","IE000M9KFDE8.USD","LU1935042991.SGD","LU0211327993.USD","ABBV","BK4566","LU0795875086.SGD","SG9999003800.SGD","JNJ","SG9999015986.USD","LU0345769128.USD","LU1244550577.SGD","SG9999015952.SGD","161121","LU1267930573.SGD","LU2750360641.GBP","LU1914381329.SGD","LU2023251221.USD","LU0320765646.SGD","IE0009355771.USD","BK4559","LU0058720904.USD","LU0128525929.USD","LU1066051811.HKD","LU0689626769.HKD","LU1983299246.USD","LU0122379950.USD","LU1267930813.SGD","LU1732799900.SGD","LU1496350171.SGD","BK4585","IE00B4R5TH58.HKD","LU2237443895.HKD","IE00BGHQF631.EUR","LU0158827948.USD","LU1989772923.USD","IE00BVYPNW00.USD","LU0661504455.SGD","LU0792757196.USD","LU1074936037.SGD","LU0545039389.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1144992166","title":"Alloy Therapeutics与艾伯维达成多年合作协议 将获首付款及平台交付相关额外付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1144992166","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144992166?lang=zh_cn&edition=full","pubTime":"2026-03-17 18:08","pubTimestamp":1773742110,"startTime":"0","endTime":"0","summary":"生物技术公司Alloy Therapeutics宣布与艾伯维公司达成一项多年期战略合作。根据协议条款，Alloy Therapeutics将获得一笔首付款，并在向艾伯维交付其专属技术平台后触发额外付款机制。此次合作将整合Alloy Therapeutics的创新平台技术与艾伯维在药物研发领域的专业优势，共同推进新型疗法的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0965508806.USD","LU1244550577.SGD","LU0256863811.USD","LU2129689514.USD","LU0553294199.USD","LU0114720955.EUR","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU2237443978.SGD","LU0417517546.SGD","LU0234570918.USD","LU0985320562.USD","LU0211328371.USD","LU0320765646.SGD","LU2237443382.USD","LU1732800096.USD","LU1037948897.HKD","LU1989772923.USD","LU2089284900.SGD","LU2023251221.USD","LU0795875169.SGD","LU0069063385.USD","LU1037948541.HKD","LU0057025933.USD","LU0965509283.SGD","LU0795875086.SGD","LU0310800379.SGD","LU0949170772.SGD","LU1551013425.SGD","IE00BLSP4452.SGD","LU1934455863.HKD","IE00BSNM7G36.USD","SG9999011175.SGD","LU1551013342.USD","LU2129689605.HKD","LU0456855351.SGD","LU0738911758.USD","LU0211327993.USD","LU0882574055.USD","LU1585245621.USD","LU1291159041.SGD","LU0965509101.SGD","LU0708994859.HKD","LU0689472784.USD","LU2112291526.USD","BK4550","SG9999015945.SGD","SG9999015986.USD","LU1718418525.SGD","LU2468319806.SGD","BK4585","IE00BLSP4239.USD","IE00BVYPNW00.USD","BK4581","BK4534","LU2087621335.USD","IE0002141913.USD","LU2237443465.HKD","BK4588","IE0004445239.USD","IE00BJJMRZ35.SGD","LU1929549753.HKD","LU1162221912.USD","IE00B2B36J28.USD","LU0545039389.USD","IE00B19Z3B42.SGD","LU0256863902.USD","LU1074936037.SGD","LU1023059063.AUD","IE00BGHQF631.EUR","IE00B4R5TH58.HKD","IE00B19Z3581.USD","LU0661504455.SGD","LU0310799852.SGD","LU0122379950.USD","SG9999015978.USD","LU2347655156.SGD","LU1839511570.USD","LU0198837287.USD","LU0689626769.HKD","LU0289739699.SGD","LU0912757837.SGD","IE00BVYPNV92.GBP","LU1093756325.SGD","IE00BDGV0183.EUR","IE00B3PB1722.GBP","BK4559","LU1732799900.SGD","BK4566","LU1989771016.USD","IE0002270589.USD","LU0098860793.USD","LU2089984988.USD","BK4139","LU1093756168.USD","LU1934455194.USD","ABBV","LU1496350171.SGD","LU0965509010.AUD","LU1934455277.USD","IE00BJT1NW94.SGD","IE00B42XCP33.USD","LU1267930490.SGD","IE00BN8TJ469.HKD","LU2237443622.USD","LU1057294990.SGD","IE0009355771.USD","LU0943347566.SGD","LU0058720904.USD","LU1003077747.HKD","LU0128525929.USD","LU0820561909.HKD","LU0511384066.AUD","LU0861579265.USD","LU0289961442.SGD","LU0820561818.USD","LU2089283258.USD","SG9999015952.SGD","LU0029864427.USD","LU0203345920.USD","LU0203347892.USD","IE00BBT3K403.USD","LU0432979614.USD","LU2129689431.USD","LU2237443549.SGD","LU0158827948.USD","LU0124676726.USD","LU0472753341.HKD","SG9999003800.SGD","LU2133065610.SGD","LU1267930573.SGD","SG9999001440.SGD","LU1496350502.SGD","LU1244550221.USD","LU1983299246.USD","LU2237443895.HKD","BK4533","LU0234572021.USD","LU0289739343.SGD","LU1244550494.USD","LU1989772840.SGD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619517271","title":"艾伯维(ABBV.US)乌帕替尼缓释片新适应症拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2619517271","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619517271?lang=zh_cn&edition=full","pubTime":"2026-03-13 09:23","pubTimestamp":1773365020,"startTime":"0","endTime":"0","summary":"艾伯维(ABBV.US)乌帕替尼缓释片的一项新适应症拟纳入优先审评，拟用于治疗成人和12岁及以上青少年的非节段型白癜风。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313092241_16037.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313092241_16037.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0124676726.USD","LU0820561909.HKD","LU1162221912.USD","IE00BGHQF631.EUR","LU0256863902.USD","LU0689472784.USD","BK4534","LU0417517546.SGD","LU0203345920.USD","LU2089284900.SGD","LU1496350171.SGD","LU0432979614.USD","ABBV","LU0211328371.USD","LU1989772923.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1929549753.HKD","LU2129689431.USD","LU1732799900.SGD","BK4588","LU1430594728.SGD","LU0234570918.USD","LU0057025933.USD","LU1037948897.HKD","BK4566","LU2237443895.HKD","LU0985320562.USD","LU2087621335.USD","LU0289739343.SGD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU1496350502.SGD","LU2023251221.USD","IE00B42XCP33.USD","LU1839511570.USD","LU0029864427.USD","LU1244550221.USD","LU0289739699.SGD","LU1244550494.USD","LU1244550577.SGD","LU0234572021.USD","LU0472753341.HKD","LU0965509010.AUD","LU1732800096.USD","BK4533","LU0965508806.USD","LU1551013342.USD","LU2112291526.USD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130607281","title":"艾伯维合作伙伴Gubra宣布ABBV-295一期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1130607281","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130607281?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:42","pubTimestamp":1773060162,"startTime":"0","endTime":"0","summary":"艾伯维公司近日公布其长效胰淀素类似物ABBV-295的一期多剂量递增试验数据，结果显示该药物表现出良好的耐受性。与安慰剂组相比，ABBV-295治疗组患者体重出现剂量依赖性显著下降，且减重幅度具备临床意义。\n此次数据为ABBV-295作为慢性体重管理差异化疗法的后续开发提供了有力支持。该药物有望为肥胖症治疗领域带来新的突破。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0234572021.USD","IE00BBT3K403.USD","LU0965509101.SGD","LU0069063385.USD","LU0211327993.USD","LU0689472784.USD","LU0820561818.USD","SG9999001440.SGD","IE0002270589.USD","LU1291159041.SGD","LU1983299246.USD","LU0965508806.USD","LU1057294990.SGD","LU0882574055.USD","SG9999015978.USD","LU0124676726.USD","LU0320765646.SGD","IE00B19Z3581.USD","LU1934455863.HKD","LU0965509010.AUD","LU0122379950.USD","LU2129689431.USD","LU1989771016.USD","IE00B3PB1722.GBP","LU0545039389.USD","SG9999003800.SGD","BK4550","BK4585","LU0861579265.USD","IE00BLSP4452.SGD","LU2237443622.USD","LU0553294199.USD","LU0256863902.USD","LU0310799852.SGD","LU0943347566.SGD","LU1074936037.SGD","LU0058720904.USD","LU1023059063.AUD","LU0256863811.USD","LU1551013342.USD","LU2237443465.HKD","LU0912757837.SGD","BK4559","LU2112291526.USD","IE00BJJMRZ35.SGD","IE00BGHQF631.EUR","LU0198837287.USD","LU1430594728.SGD","IE0002141913.USD","LU2237443382.USD","LU2087621335.USD","LU1244550221.USD","LU0234570918.USD","SG9999015952.SGD","LU0128525929.USD","LU1093756168.USD","LU0289961442.SGD","LU0432979614.USD","LU0098860793.USD","LU1929549753.HKD","LU1934455277.USD","LU0795875086.SGD","LU0661504455.SGD","LU1244550577.SGD","IE00BJT1NW94.SGD","LU0170899867.USD","LU1037948541.HKD","LU2089284900.SGD","LU1989772923.USD","LU0472753341.HKD","LU0820561909.HKD","LU0203347892.USD","LU1732800096.USD","LU2468319806.SGD","LU0949170772.SGD","BK4533","LU0417517546.SGD","LU1551013425.SGD","IE00BSNM7G36.USD","LU0289739699.SGD","LU1003077747.HKD","LU1585245621.USD","IE00B42XCP33.USD","LU0114720955.EUR","LU0965509283.SGD","IE00BVYPNW00.USD","LU1093756325.SGD","LU0289739343.SGD","LU0211328371.USD","SG9999015986.USD","LU2347655156.SGD","LU1934455194.USD","LU2237443895.HKD","BK4581","LU0057025933.USD","IE00BN8TJ469.HKD","IE00BFTCPJ56.SGD","LU1061106388.HKD","ABBV","LU1496350171.SGD","SG9999015945.SGD","LU1839511570.USD","IE0009355771.USD","SG9999011175.SGD","IE00BDGV0183.EUR","LU0456855351.SGD","LU0738911758.USD","LU2089984988.USD","IE00BVYPNV92.GBP","LU1718418525.SGD","LU0203345920.USD","LU2089283258.USD","LU2129689514.USD","LU0029864427.USD","IE00B4R5TH58.HKD","LU0511384066.AUD","LU0689626769.HKD","LU1244550494.USD","LU1989772840.SGD","LU2133065610.SGD","LU2237443549.SGD","LU2237443978.SGD","LU1267930490.SGD","LU1162221912.USD","BK4588","LU0795875169.SGD","BK4566","BK4139","IE0004445239.USD","LU1267930573.SGD","LU0158827948.USD","IE00BLSP4239.USD","BK4534","LU0708994859.HKD","LU0985320562.USD","LU1732799900.SGD","LU1496350502.SGD","LU2023251221.USD","LU1037948897.HKD","LU2129689605.HKD","LU0310800379.SGD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168779828","title":"艾伯维公布长效胰淀素类似物ABBV-295一期多剂量递增研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168779828","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168779828?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:01","pubTimestamp":1773057693,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，其长效胰淀素类似物ABBV-295在成人受试者中开展的一期多剂量递增研究获得积极顶线数据。该结果标志着该药物在临床开发阶段取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443549.SGD","LU1037948897.HKD","LU1162221912.USD","IE00BSNM7G36.USD","BK4588","IE00BN8TJ469.HKD","SG9999015952.SGD","LU0158827948.USD","LU0965509101.SGD","LU1718418525.SGD","IE00BLSP4452.SGD","LU0058720904.USD","LU0417517546.SGD","LU0882574055.USD","LU0170899867.USD","LU1244550494.USD","LU0069063385.USD","LU1074936037.SGD","LU2089283258.USD","LU1551013425.SGD","IE00BBT3K403.USD","LU0289961442.SGD","LU2237443382.USD","LU1244550221.USD","LU1267930573.SGD","LU0211327993.USD","LU2133065610.SGD","LU2347655156.SGD","LU0320765646.SGD","ABBV","LU0985320562.USD","LU0310799852.SGD","LU0708994859.HKD","LU1839511570.USD","LU0545039389.USD","BK4550","BK4585","LU1934455863.HKD","SG9999001440.SGD","LU2129689605.HKD","LU1291159041.SGD","LU0965509283.SGD","LU0114720955.EUR","LU0943347566.SGD","LU0689472784.USD","LU1023059063.AUD","LU1496350502.SGD","IE00B3PB1722.GBP","LU2087621335.USD","LU0289739699.SGD","LU2237443465.HKD","LU0661504455.SGD","LU1989771016.USD","LU1585245621.USD","LU2112291526.USD","LU2023251221.USD","IE00B2B36J28.USD","LU0949170772.SGD","LU0965508806.USD","LU0820561909.HKD","LU1430594728.SGD","IE00BVYPNV92.GBP","BK4533","LU0234570918.USD","IE00BJJMRZ35.SGD","LU0203345920.USD","LU0128525929.USD","BK4534","LU1934455194.USD","LU1983299246.USD","LU0122379950.USD","LU2468319806.SGD","LU1093756325.SGD","LU2089284900.SGD","LU0198837287.USD","LU0234572021.USD","IE00B4R5TH58.HKD","LU0029864427.USD","BK4566","IE0002270589.USD","LU1061106388.HKD","LU2129689431.USD","IE00BVYPNW00.USD","LU0820561818.USD","BK4559","LU0861579265.USD","IE0002141913.USD","LU0256863811.USD","LU0098860793.USD","LU2129689514.USD","IE00B42XCP33.USD","LU0738911758.USD","LU0256863902.USD","BK4581","IE00BFTCPJ56.SGD","LU0211328371.USD","LU0965509010.AUD","LU1989772923.USD","LU2237443895.HKD","LU1496350171.SGD","IE0004445239.USD","LU1732800096.USD","SG9999003800.SGD","LU0289739343.SGD","IE00BLSP4239.USD","LU1989772840.SGD","LU1934455277.USD","LU1929549753.HKD","LU1267930490.SGD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU0310800379.SGD","IE00B19Z3581.USD","SG9999015945.SGD","LU0456855351.SGD","LU1551013342.USD","LU1003077747.HKD","SG9999015978.USD","LU0057025933.USD","LU0203347892.USD","IE00BJT1NW94.SGD","SG9999015986.USD","IE0009355771.USD","LU2089984988.USD","IE00BGHQF631.EUR","IE00BDGV0183.EUR","LU0553294199.USD","LU0912757837.SGD","BK4139","LU0432979614.USD","LU0795875086.SGD","LU1093756168.USD","LU0689626769.HKD","LU1244550577.SGD","LU2237443978.SGD","LU2237443622.USD","LU0124676726.USD","LU1057294990.SGD","LU0472753341.HKD","LU1732799900.SGD","LU0795875169.SGD","LU1037948541.HKD","LU0511384066.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142685342","title":"艾伯维高管预计2024至2029年每股收益增长将超越高个位数复合年收入增速预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1142685342","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142685342?lang=zh_cn&edition=full","pubTime":"2026-03-04 00:33","pubTimestamp":1772555593,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日透露，在2024年至2029年期间，公司预计将实现超越高个位数复合年收入增长目标的每股收益扩张。这一展望凸显了企业通过运营效率提升和利润结构优化，持续推动盈利指标突破营收增长天花板的战略能力。相较于市场普遍关注的收入增长轨迹，管理层更强调每股收益的弹性增长空间，反映出其对于资本配置效率和股东回报的前瞻性布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","ABBV","BK4559","IE00BVYPNV92.GBP","IE00BSNM7G36.USD","LU0234570918.USD","LU0965509283.SGD","IE0002270589.USD","LU2129689605.HKD","LU1989772923.USD","LU1057294990.SGD","LU1983299246.USD","LU1093756325.SGD","LU0128525929.USD","LU1162221912.USD","LU0545039389.USD","IE00BLSP4452.SGD","LU0211327993.USD","LU1989772840.SGD","IE0009355771.USD","LU0943347566.SGD","LU0114720955.EUR","LU0256863902.USD","IE00BJT1NW94.SGD","LU0553294199.USD","LU1585245621.USD","LU0661504455.SGD","LU1989771016.USD","SG9999015952.SGD","LU0912757837.SGD","LU0289961442.SGD","LU1929549753.HKD","LU0158827948.USD","LU0211328371.USD","BK4534","LU0689472784.USD","IE00BDGV0183.EUR","IE00BGHQF631.EUR","LU0124676726.USD","IE00B42XCP33.USD","LU1074936037.SGD","IE0002141913.USD","LU1061106388.HKD","LU0456855351.SGD","LU1244550221.USD","LU0289739343.SGD","LU2468319806.SGD","LU2129689431.USD","LU1934455863.HKD","LU0289739699.SGD","LU0820561909.HKD","LU1267930573.SGD","LU0795875169.SGD","LU1291159041.SGD","LU0310800379.SGD","LU0861579265.USD","LU2089284900.SGD","LU0965508806.USD","LU1267930490.SGD","LU0058720904.USD","LU1023059063.AUD","LU0203347892.USD","LU1718418525.SGD","LU1732800096.USD","LU2237443465.HKD","IE00BLSP4239.USD","LU0949170772.SGD","LU0256863811.USD","LU2112291526.USD","BK4533","LU0198837287.USD","LU0310799852.SGD","LU2133065610.SGD","LU0820561818.USD","LU0057025933.USD","LU1037948897.HKD","LU0029864427.USD","LU0738911758.USD","LU2087621335.USD","IE00B4R5TH58.HKD","LU2089283258.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BVYPNW00.USD","LU2237443549.SGD","IE00B19Z3581.USD","LU1093756168.USD","LU2237443978.SGD","SG9999003800.SGD","LU0985320562.USD","BK4581","LU0511384066.AUD","LU1496350502.SGD","LU0320765646.SGD","LU1037948541.HKD","LU2237443622.USD","SG9999011175.SGD","LU0069063385.USD","LU1732799900.SGD","SG9999001440.SGD","IE00B3PB1722.GBP","LU0417517546.SGD","LU0122379950.USD","LU1551013342.USD","IE00BBT3K403.USD","LU1244550494.USD","LU0098860793.USD","LU0472753341.HKD","LU1934455194.USD","LU2089984988.USD","BK4588","LU0795875086.SGD","BK4550","LU0432979614.USD","LU2347655156.SGD","LU1244550577.SGD","IE00B19Z3B42.SGD","LU2237443895.HKD","LU1551013425.SGD","LU1839511570.USD","LU0689626769.HKD","SG9999015978.USD","SG9999015986.USD","LU2023251221.USD","BK4585","IE0004445239.USD","IE00BN8TJ469.HKD","LU0708994859.HKD","LU1430594728.SGD","SG9999015945.SGD","LU0234572021.USD","LU0965509010.AUD","BK4566","LU2129689514.USD","LU0965509101.SGD","LU1934455277.USD","LU2237443382.USD","LU1496350171.SGD","LU0203345920.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU1003077747.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128147669","title":"艾伯维高管称将评估Skyrizi皮下制剂在溃疡性结肠炎诱导期的应用——TD Cowen会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1128147669","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128147669?lang=zh_cn&edition=full","pubTime":"2026-03-04 00:27","pubTimestamp":1772555233,"startTime":"0","endTime":"0","summary":"艾伯维公司高管在TD Cowen会议上表示，计划对皮下注射型Skyrizi在溃疡性结肠炎诱导治疗阶段的效果展开临床评估。该举措旨在探索更便捷的给药方式对中重度患者疾病控制的潜力，若验证成功可能为患者提供传统静脉输注之外的替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689626769.HKD","LU2129689431.USD","LU1718418525.SGD","IE00B19Z3581.USD","BK4581","SG9999015952.SGD","IE00BLSP4239.USD","IE00BJT1NW94.SGD","LU0029864427.USD","LU1267930490.SGD","BK4559","LU0256863902.USD","BK4550","LU0158827948.USD","LU0861579265.USD","LU0256863811.USD","SG9999011175.SGD","LU0511384066.AUD","LU1037948897.HKD","LU0965508806.USD","LU0820561909.HKD","LU1162221912.USD","LU2237443549.SGD","LU0820561818.USD","LU0689472784.USD","IE00B19Z3B42.SGD","LU0545039389.USD","IE00B4R5TH58.HKD","LU1003077747.HKD","LU2089284900.SGD","LU2237443465.HKD","LU1839511570.USD","LU1023059063.AUD","LU0985320562.USD","LU0289739343.SGD","LU0965509010.AUD","LU1057294990.SGD","LU1093756168.USD","LU1244550221.USD","SG9999001440.SGD","LU1291159041.SGD","IE0002141913.USD","IE0002270589.USD","LU0456855351.SGD","BK4533","LU0310800379.SGD","LU2347655156.SGD","LU0203345920.USD","BK4588","IE00BVYPNV92.GBP","LU2129689605.HKD","SG9999015945.SGD","LU0417517546.SGD","LU0114720955.EUR","ABBV","LU0128525929.USD","LU1430594728.SGD","LU0203347892.USD","LU0211328371.USD","LU1989772923.USD","LU1551013342.USD","SG9999003800.SGD","LU0122379950.USD","LU2112291526.USD","LU1037948541.HKD","LU1934455194.USD","LU0234570918.USD","LU0912757837.SGD","LU0057025933.USD","LU1267930573.SGD","LU2237443978.SGD","LU2023251221.USD","LU1929549753.HKD","LU0943347566.SGD","LU2129689514.USD","LU0098860793.USD","LU0738911758.USD","LU2133065610.SGD","LU1989771016.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","LU2468319806.SGD","LU0289961442.SGD","LU0432979614.USD","LU2237443895.HKD","LU0124676726.USD","LU0795875169.SGD","LU2089283258.USD","LU0661504455.SGD","IE00B42XCP33.USD","LU1061106388.HKD","IE00B2B36J28.USD","LU1093756325.SGD","IE0004445239.USD","LU1551013425.SGD","LU0058720904.USD","SG9999015986.USD","IE00BLSP4452.SGD","LU1732799900.SGD","IE00BJJMRZ35.SGD","LU0234572021.USD","LU1983299246.USD","LU0965509283.SGD","LU0472753341.HKD","BK4566","LU0289739699.SGD","IE00BBT3K403.USD","LU0949170772.SGD","IE00BDGV0183.EUR","IE00BSNM7G36.USD","LU2087621335.USD","BK4139","IE00BN8TJ469.HKD","LU2237443622.USD","LU0882574055.USD","IE0009355771.USD","LU1934455863.HKD","LU0320765646.SGD","LU0211327993.USD","LU0708994859.HKD","LU1732800096.USD","BK4585","LU0553294199.USD","LU0795875086.SGD","IE00BVYPNW00.USD","LU0198837287.USD","LU1496350502.SGD","LU0965509101.SGD","IE00B3PB1722.GBP","LU1934455277.USD","BK4534","LU1496350171.SGD","LU0170899867.USD","LU2089984988.USD","LU1244550494.USD","LU1989772840.SGD","LU1074936037.SGD","SG9999015978.USD","LU1244550577.SGD","IE00BGHQF631.EUR","LU0310799852.SGD","LU0069063385.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136205999","title":"艾伯维公布Skyrizi®（利生奇单抗）治疗克罗恩病皮下诱导三期Affirm研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136205999","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136205999?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:31","pubTimestamp":1772458275,"startTime":"0","endTime":"0","summary":"艾伯维公司近日宣布，其评估Skyrizi®（利生奇单抗）皮下诱导方案用于克罗恩病患者的第三阶段Affirm研究取得了积极的顶线结果。该研究达到了其主要终点，显示出显著的治疗效果。\n这一突破性进展为克罗恩病患者提供了新的潜在治疗选择，进一步巩固了Skyrizi®在自身免疫性疾病治疗领域的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310799852.SGD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU1496350171.SGD","IE00BJT1NW94.SGD","LU0708994859.HKD","LU1267930573.SGD","LU2237443895.HKD","LU0949170772.SGD","LU0289961442.SGD","LU1023059063.AUD","LU0965509101.SGD","LU2129689514.USD","BK4581","LU0472753341.HKD","LU2468319806.SGD","IE0004445239.USD","SG9999011175.SGD","LU1934455863.HKD","LU0965509283.SGD","LU0965509010.AUD","BK4534","LU0795875169.SGD","LU1093756325.SGD","SG9999015952.SGD","LU0820561818.USD","LU0170899867.USD","LU0057025933.USD","IE00B4R5TH58.HKD","LU2089284900.SGD","LU0861579265.USD","LU0289739343.SGD","LU0553294199.USD","LU0256863811.USD","LU0289739699.SGD","LU2133065610.SGD","BK4550","LU1934455277.USD","LU1162221912.USD","LU1244550221.USD","LU2023251221.USD","LU2089984988.USD","LU0511384066.AUD","LU2087621335.USD","LU0912757837.SGD","LU1934455194.USD","LU0198837287.USD","LU2237443382.USD","LU1244550577.SGD","LU0029864427.USD","LU0985320562.USD","SG9999001440.SGD","LU0203347892.USD","LU1074936037.SGD","IE0002270589.USD","LU0114720955.EUR","LU1291159041.SGD","LU0211328371.USD","LU2237443978.SGD","LU1430594728.SGD","LU0417517546.SGD","LU0069063385.USD","LU1989771016.USD","LU1732799900.SGD","IE00BLSP4452.SGD","IE00BGHQF631.EUR","IE00BDGV0183.EUR","LU1057294990.SGD","LU0820561909.HKD","LU0124676726.USD","IE00BFTCPJ56.SGD","BK4139","LU0320765646.SGD","LU1585245621.USD","LU2112291526.USD","LU1929549753.HKD","LU1061106388.HKD","LU1267930490.SGD","LU1244550494.USD","LU0058720904.USD","LU0203345920.USD","IE00BN8TJ469.HKD","LU0098860793.USD","LU0689626769.HKD","LU1983299246.USD","IE00B19Z3581.USD","LU0456855351.SGD","SG9999003800.SGD","LU1037948541.HKD","LU1003077747.HKD","LU1496350502.SGD","IE00BLSP4239.USD","LU1037948897.HKD","BK4559","IE00B19Z3B42.SGD","LU0661504455.SGD","LU0234570918.USD","LU1989772840.SGD","LU2237443465.HKD","BK4533","IE00B3PB1722.GBP","IE00B2B36J28.USD","SG9999015978.USD","IE00BVYPNV92.GBP","LU1093756168.USD","LU0128525929.USD","LU2347655156.SGD","LU0943347566.SGD","BK4566","BK4585","LU2237443549.SGD","LU1551013425.SGD","SG9999015986.USD","IE00BVYPNW00.USD","IE0002141913.USD","IE00BSNM7G36.USD","IE00BBT3K403.USD","LU0256863902.USD","LU2129689605.HKD","LU2089283258.USD","LU1718418525.SGD","LU1839511570.USD","LU0234572021.USD","SG9999015945.SGD","LU0882574055.USD","LU1989772923.USD","LU0432979614.USD","LU0795875086.SGD","IE00B42XCP33.USD","LU2129689431.USD","LU0211327993.USD","LU0689472784.USD","LU2237443622.USD","LU0158827948.USD","BK4588","LU0965508806.USD","ABBV","LU0310800379.SGD","LU1732800096.USD","LU1551013342.USD","IE0009355771.USD","LU0738911758.USD","LU0545039389.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0475},{"period":"3month","weight":-0.0979},{"period":"6month","weight":-0.0804},{"period":"1year","weight":0.0861},{"period":"ytd","weight":-0.1179}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.019222},{"month":2,"riseRate":0.857143,"avgChangeRate":0.039081},{"month":3,"riseRate":0.714286,"avgChangeRate":0.001102},{"month":4,"riseRate":0.571429,"avgChangeRate":0.006536},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.001294},{"month":6,"riseRate":0.461538,"avgChangeRate":0.008788},{"month":7,"riseRate":0.538462,"avgChangeRate":0.01232},{"month":8,"riseRate":0.538462,"avgChangeRate":0.007409},{"month":9,"riseRate":0.538462,"avgChangeRate":0.014941},{"month":10,"riseRate":0.615385,"avgChangeRate":0.007438},{"month":11,"riseRate":0.769231,"avgChangeRate":0.063841},{"month":12,"riseRate":0.692308,"avgChangeRate":0.025718}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}